To enhance the affinity for Gas6 binding, decoy receptors with engineered mutations in the AXL extracellular domain have been developed and treatment with these high affinity proteins decreased tumor metastasis in murine models of ovarian cancer and breast cancer [124]. Here, GAS6 is linked to neoplasm.